Despite NuThrax’s failure to win FDA approval, almost half of the Strategic National Stockpile’s half-billion-dollar annual budget prior to 2020 went to Emergent’s two anthrax vaccines—a cost that, according to the New York Times, “left the government with less money to buy supplies needed in a pandemic.”
